Summary p53 alterations at the DNA, mRNA and protein levels were studied in tumour metastases sampled from 30 patients with malignant melanoma. Paraffin-embedded sections from these and an additional 12 patients were examined for the presence of p53 protein. TP53 gene aberrations were found in 7 of 30 (23%) of the patients, six of which showed loss of heterozygosity (LOH). Point mutations were detected in only two cases, one of which had LOH whereas the other was non-informative. Increased levels of p53 mRNA were present in only one tumour with, but in six cases without, detectable DNA abnormalities. Four of the latter and six tumours with normal transcript levels had immunohistochemically detectable levels of p53 protein. In 25 cases in which corresponding primary and metastatic lesions could be compared, closely similar immunoreactivity patterns were observed. Increased expression of the MDM2 gene was found in only one tumour in parallel with overexpression of p53. Altogether, the data indicate that inactivation of the p53 regulatory pathway is not of major significance in the tumorigenesis of malignant melanoma. However, a significant association was found between p53 immunoreactivity and the relapse-free period in patients with superficial spreading melanoma. That increased protein expression was predominantly found in tumours without DNA alterations might suggest a role for the wild-type p53 protein in restricting malignant cell proliferation in these cases.
The TP53 gene, which is localised to chromosome fragment l7pl3 (Isobe et al., 1986) , appears to be one of the genes most commonly altered in human cancer cells (Vogelstein, 1990; Caamano et al., 1992; Andreassen et al., 1993) . The gene encodes a nuclear phosphoprotein that has been suggested to function as a control factor in the repair of damaged DNA (Kastan et al., 1991) and in cell growth control by acting as a transcriptional regulator (Levine et al., 1991) .
Loss of protein function may occur when a mutation is accompanied by a deletion in the remaining allele (Nigro et al., 1989) . Furthermore, it has been suggested that mutated p53 and other proteins may bind and inactivate wild-type p53 (Kraiss et al., 1988; Lehman et al., 1991) . Thus, the mdm2 (murine double minute 2) gene product has been shown to interact with both wild-type and mutated p53, thereby inhibiting p53-mediated transactivation in a dosedependent manner (Momand et al., 1992) . Moreover, MDM2 amplification and overexpression have been shown in a substantial number of sarcomas and glioblastomas with normal TP53 (Oliner et al., 1992; Ladanyi et al., 1993; Reifenberger et al., 1993; Fl0renes et al., submitted) , suggesting that alterations involving these two genes are alternative mechanisms for escaping p53-regulated growth control (Oliner et al., 1992) .
Wild-type p53 is known to have a very short half-life , whereas most TP53 mutations result in a stabilised protein. Recently, however, evidence has been obtained suggesting that under some circumstances wild-type p53 may also accumulate in cells, probably by complex formation with other proteins or by oligomerisation (Lehman et al., 1991) . In accordance with this, accumulation of wild-type p53 has been observed in proliferating, mitogen-stimulated lymphocytes (Rivas et al., 1992) and in the basal layer of human skin in response to mild UV irradiation (Hall et al., 1993) .
Relatively few reports on p53 aberrations in melanoma have been published. In the Li-Fraumeni syndrome, in which melanoma represents one of the tumour forms, inherited TP53 mutations seem to be present in around 70% of the cases examined (S. Friend, personal communication). Among nine human melanoma cell lines, a point mutation within the TP53 gene was found in only one (Volkenandt et al., 1991) . In contrast, p53 protein, as detected by immunohistochemistry, has been reported to be present in a very high percentage (70-98%) of melanomas (Stretch et al., 1991; Akslen & Morkve, 1992) .
The aim of the present work was to study a panel of malignant melanomas of different histological subtypes and at different stages of disease progression for TP53 allele deletions, gene mutation and the tumour levels of p53 mRNA and protein. Attempts were also made to relate the p53 status to the mRNA expression of mdm2 and to known clinical parameters for melanoma progression.
Materials and methods

Specimens
Fresh tumour tissue from metastatic lesions and peripheral blood cells were sampled from 30 patients with malignant melanoma. Upon surgical removal the tissue was frozen immediately at -135C. Formalin-fixed, paraffin-embedded sections of melanoma metastases were obtained from the same 30 patients and from an additional 12 patients. Archival paraffin-embedded tissue from the primary tumour was obtained in 25 cases, and in seven cases material from different metastases, appearing at various stages of the disease, was available for examination. Nineteen of the 42 melanomas were classified as superficial, 13 as nodular, six belonged to other histological subgroups, and the primary tumour was unknown in four cases.
Southern blot analysis Genomic DNA from melanoma tissues and peripheral blood cells was isolated by standard methods (Maniatis et al., 1982) . Aliquots (10 pg) of DNA were digested with an appropriate restriction enzyme, separated on 0.8% agarose gels and transferred onto Hybond-N+ membranes (Amersham, Amersham, UK), according to the manufacturer's manual. After baking for 2 h at 80°C and subsequent UV crosslinking, the blots were hybridised with DNA probes labelled with 32P by the random primer technique (Feinberg & Vogelstein, 1983) . The hybridisation was carried out in 0.5 M sodium phosphate pH 7.2, 7% SDS and 1 mM sodium EDTA at 65°C for 16 h as described by Church and Gilbert (1984) . After hybridisation, the membranes were washed three times for 20 min in 40 mM sodium phosphate (pH 7.2) and 1% SDS. For multiple hybridisations, the bound probe was removed by incubating the filters twice for 5 min in 0.1 x standard saline citrate (2 x SSE = 3.0 M sodium chloride, 0.3M sodium citrate, pH 7.0) and 0.1% SDS at 95-100°C.
Probes and restriction enzymes
To detect allelic deletions within the area of the TP53 gene on chromosome fragment 17p, the following probes and restriction enzymes were used: 144-D6 (17pl 3.3), MspI, (Kondeleon et al., 1987) ; YNZ22 (17pl3.3), TaqI, (Nakamura et al., 1988) ; pBHp53 (17pl3.1), BamHI, (H0yheim et al., 1989 ) and pHF12-2 (17pl2.2), MspI (Naylor et al., 1984 ). An MDM2 cDNA probe (Oliner et al., 1992) (1990) . The PCR products were digested with the restriction enzyme BstUI, separated by polyacrylamide gel electrophoresis and visualised by ethidium bromide staining of the gels.
The exon 6 to intron 6 region of TP53, which contains a MspI polymorphic site, was amplified using one 20-and one 24-oligomer primer as previously described (McDaniel et al., 1991; Andreassen et al., 1993) .
Mutation analysis of the TP53 gene DNA from the tumours was analysed for possible TP53 mutations using the CDGE method . The screening was performed using PCR primers amplifying codons 128-153 (fragment A) and 155-185 (fragment B) of exon 5, codons 237-253 (fragment C) of exon 7 and codons 265-301 (fragment D) of exon 8 (B0rresen et al., 1991) . Samples that showed aberrantly migrating bands, indicating mutations, were submitted to PCR performed with one biotinylated primer. The biotinylated PCR products were subsequently sequenced directly using the standard dideoxy method and Dynabeads M280-Stretavidin (Dynal, Norway) as solid support (Hultman et al., 1989) .
Northern blot analysis Total RNA was isolated from the tumours by the guanidinium thiocyanate-phenol-chloroform extraction method described by Chomczynski and Sacchi (1987) or the guanidinium thiocyanate-caesium chloride method described in Maniatis et al. (1982) . Samples of 5 sg of total RNA were resolved by electrophoresis on 1% agarose-formaldehyde gels (Maniatis et al., 1982) , blotted in 10 x standard saline citrate onto Hybond-N + membranes (Amersham), baked, stripped and hybridised to a kinase-labelled human p53 40-mer oligonucleotide probe as recommended by the manufacturer (Oncogene Science), and to a kinase-labelled (Maniatis et al., 1982) oligonucleotide specific for human 18S rRNA to correct for unequal RNA loading.
Immunohistochemistry
Sections from formalin-fixed, paraffin-embedded tissues were immunostained using the avidin-biotin-peroxidase complex (ABC) method described by Hsu et al. (1981) . Briefly, the sections were incubated for 18-22h at 4°C with the polyclonal p53 antiserum NCL-CM1 (Novocastra Laboratories), diluted 1:500, or with the monoclonal antibody PAb 1801 (Oncogene Science), diluted 1: 100 (1 jig IgGl ml 1), followed by sequential incubations with biotin-labelled secondary antibody and avidin-biotin-peroxidase complex. The reaction was finally developed using diaminobenzidine as chromogen. All series included positive controls. Negative controls included substitution of polyclonal primary antiserum with normal rabbit serum diluted 1:300, whereas negative controls for the monoclonal antibody were performed using mouse myeloma protein of the same subclass and concentration as the monoclonal antibody. Four semiquantitative classes were used to describe the number of positively stained tumour cells: (-) none, (+) <5%, (+ +) 5-50%, (+++) >50%.
Clinical parameters
The following clinical parameters for disease progression were assessed: localisation of the primary tumour, depth of growth in millimetres, and relapse-free period (months) from diagnosis of the primary tumour to development of distant metastasis.
Results
RFLP studies DNA from 30 matched pairs of melanoma metastases and peripheral blood cells was studied for LOH on chromosome fragment 17p. As summarised in Figure 1 , the tumours of seven patients (23%) had lost one or more alleles of the examined loci. In one additional case (No. 9) a rearranged (abnormal) band pattern was found with the YNZ22 probe.
Using the pBHp53 probe, which is located close to the TP53 locus, three (nos. 1, 3 and 5) of 10 (30%) informative cases showed LOH, and in one additional case (no. 2) a rearranged band pattern plus an extra restriction fragment was observed. In the 29 cases in which PCR-RFLP analyis of codon 72 (exon 4) and of the exon 6 to intron 6 region of the TP53 gene could be performed, LOH within codon 72 was found in 3 of 13 (23%) informative cases (nos. 2, 4 and 6). In addition, the loss of codon 72 on both TP53 alleles was detected in two cases (nos. 1 and 3). In these two tumours, the deletions within codon 72 and at the pBHpS3 locus were accompanied by LOH at two polymorphic loci distal to TP53 (144-D6 and YNZ22). In case 8, LOH was found with the YNZ22 probe, whereas both codon 72 and pBHpS3 were non-informative. In only one patient (no. 5) LOH centromeric (D17S1) to TP53 was found, together with the loss detected with the pBHp53 probe. None of the informative cases showed LOH within the exon 6 to intron 6 region (not shown).
Mutation analysis
In an attempt to detect point mutations within TP53, we performed CDGE analysis covering the four 'hotspots' in exons 5, 7 and 8. Aberrantly migrating bands were found in only two (7%) of the melanoma metastases (Figure 1 ). In one of these (no. 6) a mutation within codons 155-185 (exon 5) was present together with LOH involving codon 72 (exon 4). In the other case (no. 7) the mutation was localised to codon 275 of exon 8, whereas the RFLP data from this tumour were not informative. Interestingly, upon sequencing, a TGT-*TGG transversion involving a change from cysteine to tryptophan was detected (Figure 2a) , a mutation which has not previously been described. (Table I ). In the limited number of cases studied, the patients with superficial tumours that expressed p53 protein had a significantly longer relapse-free period (mean 47 months) compared with those with no detectable amounts of p53 protein (mean 20 months) (P = 0.03; Mann-Whitney two-tailed test). The observed difference in disease progression was independent of the thickness of the primary tumour, which was about the same in both groups. No relationship was found between p53 protein expression and localisation of the primary tumours (not shown), or between TP53 gene alterations and any of the evaluated clinical parameters.
Discussion
Genetic abnormalities involving chromosomes 1, 6, 7 and 9 are frequent (44-83%) in malignant melanoma, whereas chromosome 17 alterations seem to be relatively rare. Thus, in the material reviewed by Fountain et al. (1990) , only 22%
of the melanomas were found to harbour chromosome 17 aberrations, as detected by cytogenetic analysis. Nevertheless, it has been suggested that the TP53 gene located on chromosome 17 may be involved in melanoma development, as a high fraction of tumour samples studied by immunohistochemistry stained positively for p53 protein, indicating p53 aberrations (Stretch et al., 1991; Akslen &M0rkve, 1992) . In an attempt to elucidate this possibility further, we analysed surgically removed metastatic tumours from patients with malignant melanoma for LOH on chromosome arm 17p, for TP53 point mutations and p53 mRNA levels. In addition, the metastases and the corresponding primary tumours were studied by immunocytochemistry for expression of the protein. TP53 gene aberrations were observed in the metastases of 7 of 30 (23%) melanoma patients. Six tumours showed LOH, whereas gene mutations were detected by CDGE analysis in only two cases. One of these, which was non-informative for the TP53 loci, had a mutation at codon 275 of exon 8, as identified by sequencing. The other contained a mutation in exon 5 of the gene, which unfortunately could not be confirmed upon sequencing because of the limited sensitivity of the direct squencing method (Condie et al., 1993) . That a mutation was detected in only one of six cases with LOH is in accordance with previous reports suggesting that mutations and LOH may represent independent events (Osborne et al., 1991; Coles et al., 1992; Toguchida et al., 1992) . The possibility exists that the frequency of gene mutations in our material may be underestimated, as the screening was restricted to exons 5, 7 and 8, but since more than 85% of all known TP53 mutations have been localised to exon 5-8 this possibility does not seem likely (Nigro et al., 1989; Hollstein et al., 1991 ). Tobal et al. (1992 recently suggested on the basis of findings in choroidal melanomas that abnormalities of TP53 may be important in melanoma development. However, our results, together with data obtained on a panel of 30 cases of primary and metastatic melanoma, in which no point mutations were detected (P.A. Albino, personal communication), indicate that TP53 mutations are not of major significance in the tumorigenesis of malignant cutaneous melanomas.
Previously, Akslen and M0rkve (1992) and Stretch et al. (1991) reported p53 protein immunoreactivity in 97% and 85% of malignant melanomas respectively. In contrast to their findings, only 38% of the 42 metastatic lesions and 36% of the primary melanomas in the present study expressed Akslen and M0rkve (1992) . It is noteworthy that Akslen (1993) has recently emphasised that positive staining may in some cases be artificial. The observed heterogeneity in staining pattern within each tumour found here seems to represent a common finding in different types of cancer (Stretch et al., 1991; Akslen & M0rkve, 1992; Holm et al., 1992; Pignatelli et al., 1992; Thor et al., 1992) . It has been suggested that this may result from cell cycle variations or that different mutations and wild-type p53 may exist within the same tumour (Wynford-Thomas, 1992) .
In accordance with findings obtained in squamous cell carcinoma (Dolcetti et al., 1992) and in breast cancer (Davidoff et al., 1991) It has recently been shown that p53 protein expression may be induced in the basal layer of human skin after mild exposure to UV radiation (Hall et al., 1993) . This finding makes p53 expression studies in malignant melanomas particularly interesting in the light of the association between increased incidence of melanomas and increased exposure to UV light (Koh, 1991) . It is not inconceivable that the elevated levels of p53 protein we found in normal cells surrounding two tumours may have been induced in response to UV radiation, reflecting the putative role of p53 in repairing damaged DNA (Kastan et al., 1991) and in suppressing cell proliferation (Fields & Jang, 1990) .
The p53 mRNA levels were increased in six tumours that had no detectable abnormalities of the TP53 gene, and four of these cases also showed relatively strong immunostaining for p53 protein (5-50% of stained cells). In addition, six tumours with normal mRNA levels contained areas with stained cells. These data might suggest that p53 can be involved in determining the malignant potential of the tumours in the absence of detectable DNA aberrations. The possibility that the increased protein levels may represent wild-type and not mutated protein is supported by recent reports suggesting that wild-type protein may be stabilised by complex formation with other proteins or by oligomerisation (Lehman et al., 1991) .
By its ability to complex with p53, overexpression of mdm2 has been suggested to provide an alternative pathway of inactivating p53 in cases with no abnormalities of the TP53 gene (Momand et al., 1992; Oliner et al., 1992; Ladanyi et al., 1993; Reifenberger et al., 1993) . Furthermore, an interaction between the two proteins at the transcriptional level has recently been suggested (Barak et al., 1993; Fl0renes et al., submitted) . Since overexpression of MDM2 mRNA was found here in only one case, in parallel with increased expression of p53 mRNA and protein, it is unlikely that mdm2 is of importance in the development and progression of melanoma.
Overexpression of p53 has been found to correlate with increased survival in patients with squamous cell carcinoma of the tongue (Sauter et al., 1992) , and may also indicate a better prognosis in sarcoma patients (Andreassen et al., 1992) . The apparent association between elevated p53 protein expression and a prolonged relapse-free period in our patients with superficially spreading melanoma suggests that, in these cases, increased levels of wild-type protein might help restrict the proliferative capacity and thereby the degree of malignancy of the melanoma cells. This hypothesis seems to be supported by the finding that in three patients p53 protein immunoreactivity detected in the primary tumours was lost in the corresponding metastases.
